As mentioned earlier, A-FABP plays a vital role in the development of MetS and CVD, and MetS is a risk factor for CVD-related graft loss and death after KT, suggesting that high A-FABP levels are predictive of poor graft outcome in KT patients because of the aggravation of MetS components. Here, FABP4 is linked to metabolic syndrome.